Pancreatic Cancer Research

ResearcherHospital Clínic de BarcelonaActive in the last 2 years

Laura Visa

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0002-3409-8857; OpenAlex author ID A5043472954. Sources: OpenAlex.

Their work

Papers
10 (first author 2, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
38
Papers, trials and grants by year

2012: 1 paper · 2013: none · 2014: none · 2015: none · 2016: none · 2017: none · 2018: 3 papers · 2019: none · 2020: 2 papers · 2021: 1 paper · 2022: 1 paper · 2023: none · 2024: 1 paper · 2025: none · 2026: 1 paper

Papers 10

  1. Lateral flow immunoassay detection of soluble AXL for pancreatic ductal adenocarcinoma diagnosis. Co-author DOI 10.1016/j.talanta.2026.129973↗
  2. Update on the management of older patients with pancreatic adenocarcinoma: a perspective from medical oncology. First author DOI 10.1007/s12094-024-03386-8↗
  3. Soluble AXL is a novel blood marker for early detection of pancreatic ductal adenocarcinoma and differential diagnosis from chronic pancreatitis. Co-author DOI 10.1016/j.ebiom.2021.103797↗
  4. Abdominal Wall Metastasis of Pancreatic Cancer: The Tip of the Iceberg-Case Report. Co-author DOI 10.1097/mpa.0000000000001761↗
  5. Quality of life of patients with metastatic pancreatic adenocarcinoma initiating first-line chemotherapy in routine practice. Co-author DOI 10.1186/s12904-020-00610-4↗
  6. The Galectin Family as Molecular Targets: Hopes for Defeating Pancreatic Cancer. Co-author DOI 10.3390/cells9030689↗
  7. Outcomes after neoadjuvant treatment with gemcitabine and erlotinib followed by gemcitabine-erlotinib and radiotherapy for resectable pancreatic cancer (GEMCAD… Co-author DOI 10.1007/s00280-018-3682-9↗
  8. KRAS mutations in ctDNA: a promising new biomarker in advanced pancreatic cancer Last author DOI 10.1093/annonc/mdy484↗
  9. Increased plasma levels of galectin-1 in pancreatic cancer: potential use as biomarker. Co-author DOI 10.18632/oncotarget.26034↗
  10. CA 19-9 in pancreatic cancer: retrospective evaluation of patients with suspicion of pancreatic cancer. First author DOI 10.1007/s13277-011-0297-8↗

Closest collaborators

The 25 strongest of 38 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Neus Martínez‐Bosch · 4 shared papers, 2018–2026 · strength 0.65
  2. Pilar Navarro · 4 shared papers, 2018–2026 · strength 0.65
  3. Pablo Garcı́a de Frutos · 2 shared papers, 2022–2026 · strength 0.43
  4. Teresa Mercade Macarulla · 2 shared papers, 2020–2024 · strength 0.31
  5. Núria Vázquez-Bellón · 1 shared paper, 2026 · strength 0.30
  6. J.‐Pablo Salvador · 1 shared paper, 2026 · strength 0.30
  7. Noemí Manero‐Rupérez · 2 shared papers, 2020–2022 · strength 0.27
  8. M. Guillot Morales · 1 shared paper, 2024 · strength 0.22
  9. Regina Gironés Sarrió · 1 shared paper, 2024 · strength 0.22
  10. Jaime Feliú · 1 shared paper, 2024 · strength 0.22
  11. Alfredo Carrato · 2 shared papers, 2018–2022 · strength 0.20
  12. Julie Earl · 2 shared papers, 2018–2022 · strength 0.20
  13. Luis Eduardo Casasola‐Sánchez · 1 shared paper, 2021 · strength 0.16
  14. Patricia Sánchez‐Velázquez · 1 shared paper, 2021 · strength 0.16
  15. Fernando Burdı́o · 1 shared paper, 2021 · strength 0.16
  16. Berta Laquente · 2 shared papers, 2018–2020 · strength 0.15
  17. Marta Martín-Richard · 2 shared papers, 2018–2020 · strength 0.15
  18. Joana Vidal · 1 shared paper, 2018 · strength 0.14
  19. Clara O. Montagut · 1 shared paper, 2018 · strength 0.14
  20. Meritxell Gironella · 1 shared paper, 2022 · strength 0.13
  21. Carmen E. Guerra · 1 shared paper, 2022 · strength 0.13
  22. Helena Verdaguer · 1 shared paper, 2020 · strength 0.09
  23. Adelaida Garcia-Velasco · 1 shared paper, 2020 · strength 0.09
  24. Carles Pericay · 1 shared paper, 2020 · strength 0.09
  25. Laureano Fernández‐Cruz · 2 shared papers, 2012–2018 · strength 0.09

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.